Management of isolated soleal and gastrocnemius vein thrombosis

Clifford Sales, Faheem Haq, Rami Bustami, Frances Sun

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Objective: The ideal treatment for hospitalized patients with isolated gastrocnemius and/or soleal venous thrombosis is unclear. Recommendations range from watchful waiting to full-dose anticoagulation. This study examines the effectiveness of practice patterns at a single institution as measured by progression of thrombus. Methods: All consecutive inpatients with a duplex scan diagnosis of isolated gastrocnemius and/or soleal vein clot (no other thrombotic segments were identified) and where two consecutive duplex studies (Intersocietal Commission for the Accreditation of Vascular Laboratories laboratory) were available for review were included. Two study groups were identified. TX group included patients who received anticoagulation treatment (heparin [fractionated or unfractionated], heparin substitutes, or warfarin) and the NoTX group included those who did not receive anticoagulant. Demographic, risk factors, comorbidities, length of hospital and intensive care unit stay, ambulatory status, and underlying hypercoagulable states were recorded. Thrombus progression rate in the two groups was compared using the χ2 test. A multivariate logistic regression model was used to examine the effect of anticoagulation treatment as well as the above demographic and clinical factors on the risk of progression. Results: A total of 141 patients were included in the study, 76 of whom (54%) received anticoagulation. Forty-three patients (30%) had progression of their venous thrombosis: 33% (25/76) in the TX group and 28% (18/65) in the NoTX group (P = .50, by 2 test). Results from multivariate logistic regression showed that treatment had no significant impact on outcome (Odds ratio = 1.28, 95% confidence interval: 0.55-3.01; P = .57]. Patients with end-stage renal disease (6%), or stroke (13%) had significantly higher risk of progression (P < .05). None of the other clinical or demographic factors were significantly associated with the risk of progression. Conclusion: The results speak to the lack of efficacy of anticoagulation in the management of gastrocnemius and/or soleal vein thrombosis in the hospitalized patient. When measured by thrombus progression, treating these patients without anticoagulation appears to be equally efficacious as subjecting patients to anticoagulant therapy. A prospective, randomized clinical trial will be an important step in fully addressing this clinical dilemma.

Original languageEnglish (US)
Pages (from-to)1251-1254
Number of pages4
JournalJournal of Vascular Surgery
Volume52
Issue number5
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Veins
Thrombosis
Logistic Models
Demography
Venous Thrombosis
Anticoagulants
Heparin
Watchful Waiting
Therapeutics
Accreditation
Warfarin
Chronic Kidney Failure
Blood Vessels
Intensive Care Units
Comorbidity
Inpatients
Randomized Controlled Trials
Stroke
Odds Ratio
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Sales, Clifford ; Haq, Faheem ; Bustami, Rami ; Sun, Frances. / Management of isolated soleal and gastrocnemius vein thrombosis. In: Journal of Vascular Surgery. 2010 ; Vol. 52, No. 5. pp. 1251-1254.
@article{8ea09f95c11d40debf025b8f9c3b6534,
title = "Management of isolated soleal and gastrocnemius vein thrombosis",
abstract = "Objective: The ideal treatment for hospitalized patients with isolated gastrocnemius and/or soleal venous thrombosis is unclear. Recommendations range from watchful waiting to full-dose anticoagulation. This study examines the effectiveness of practice patterns at a single institution as measured by progression of thrombus. Methods: All consecutive inpatients with a duplex scan diagnosis of isolated gastrocnemius and/or soleal vein clot (no other thrombotic segments were identified) and where two consecutive duplex studies (Intersocietal Commission for the Accreditation of Vascular Laboratories laboratory) were available for review were included. Two study groups were identified. TX group included patients who received anticoagulation treatment (heparin [fractionated or unfractionated], heparin substitutes, or warfarin) and the NoTX group included those who did not receive anticoagulant. Demographic, risk factors, comorbidities, length of hospital and intensive care unit stay, ambulatory status, and underlying hypercoagulable states were recorded. Thrombus progression rate in the two groups was compared using the χ2 test. A multivariate logistic regression model was used to examine the effect of anticoagulation treatment as well as the above demographic and clinical factors on the risk of progression. Results: A total of 141 patients were included in the study, 76 of whom (54{\%}) received anticoagulation. Forty-three patients (30{\%}) had progression of their venous thrombosis: 33{\%} (25/76) in the TX group and 28{\%} (18/65) in the NoTX group (P = .50, by 2 test). Results from multivariate logistic regression showed that treatment had no significant impact on outcome (Odds ratio = 1.28, 95{\%} confidence interval: 0.55-3.01; P = .57]. Patients with end-stage renal disease (6{\%}), or stroke (13{\%}) had significantly higher risk of progression (P < .05). None of the other clinical or demographic factors were significantly associated with the risk of progression. Conclusion: The results speak to the lack of efficacy of anticoagulation in the management of gastrocnemius and/or soleal vein thrombosis in the hospitalized patient. When measured by thrombus progression, treating these patients without anticoagulation appears to be equally efficacious as subjecting patients to anticoagulant therapy. A prospective, randomized clinical trial will be an important step in fully addressing this clinical dilemma.",
author = "Clifford Sales and Faheem Haq and Rami Bustami and Frances Sun",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.jvs.2010.05.102",
language = "English (US)",
volume = "52",
pages = "1251--1254",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "5",

}

Management of isolated soleal and gastrocnemius vein thrombosis. / Sales, Clifford; Haq, Faheem; Bustami, Rami; Sun, Frances.

In: Journal of Vascular Surgery, Vol. 52, No. 5, 01.01.2010, p. 1251-1254.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Management of isolated soleal and gastrocnemius vein thrombosis

AU - Sales, Clifford

AU - Haq, Faheem

AU - Bustami, Rami

AU - Sun, Frances

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Objective: The ideal treatment for hospitalized patients with isolated gastrocnemius and/or soleal venous thrombosis is unclear. Recommendations range from watchful waiting to full-dose anticoagulation. This study examines the effectiveness of practice patterns at a single institution as measured by progression of thrombus. Methods: All consecutive inpatients with a duplex scan diagnosis of isolated gastrocnemius and/or soleal vein clot (no other thrombotic segments were identified) and where two consecutive duplex studies (Intersocietal Commission for the Accreditation of Vascular Laboratories laboratory) were available for review were included. Two study groups were identified. TX group included patients who received anticoagulation treatment (heparin [fractionated or unfractionated], heparin substitutes, or warfarin) and the NoTX group included those who did not receive anticoagulant. Demographic, risk factors, comorbidities, length of hospital and intensive care unit stay, ambulatory status, and underlying hypercoagulable states were recorded. Thrombus progression rate in the two groups was compared using the χ2 test. A multivariate logistic regression model was used to examine the effect of anticoagulation treatment as well as the above demographic and clinical factors on the risk of progression. Results: A total of 141 patients were included in the study, 76 of whom (54%) received anticoagulation. Forty-three patients (30%) had progression of their venous thrombosis: 33% (25/76) in the TX group and 28% (18/65) in the NoTX group (P = .50, by 2 test). Results from multivariate logistic regression showed that treatment had no significant impact on outcome (Odds ratio = 1.28, 95% confidence interval: 0.55-3.01; P = .57]. Patients with end-stage renal disease (6%), or stroke (13%) had significantly higher risk of progression (P < .05). None of the other clinical or demographic factors were significantly associated with the risk of progression. Conclusion: The results speak to the lack of efficacy of anticoagulation in the management of gastrocnemius and/or soleal vein thrombosis in the hospitalized patient. When measured by thrombus progression, treating these patients without anticoagulation appears to be equally efficacious as subjecting patients to anticoagulant therapy. A prospective, randomized clinical trial will be an important step in fully addressing this clinical dilemma.

AB - Objective: The ideal treatment for hospitalized patients with isolated gastrocnemius and/or soleal venous thrombosis is unclear. Recommendations range from watchful waiting to full-dose anticoagulation. This study examines the effectiveness of practice patterns at a single institution as measured by progression of thrombus. Methods: All consecutive inpatients with a duplex scan diagnosis of isolated gastrocnemius and/or soleal vein clot (no other thrombotic segments were identified) and where two consecutive duplex studies (Intersocietal Commission for the Accreditation of Vascular Laboratories laboratory) were available for review were included. Two study groups were identified. TX group included patients who received anticoagulation treatment (heparin [fractionated or unfractionated], heparin substitutes, or warfarin) and the NoTX group included those who did not receive anticoagulant. Demographic, risk factors, comorbidities, length of hospital and intensive care unit stay, ambulatory status, and underlying hypercoagulable states were recorded. Thrombus progression rate in the two groups was compared using the χ2 test. A multivariate logistic regression model was used to examine the effect of anticoagulation treatment as well as the above demographic and clinical factors on the risk of progression. Results: A total of 141 patients were included in the study, 76 of whom (54%) received anticoagulation. Forty-three patients (30%) had progression of their venous thrombosis: 33% (25/76) in the TX group and 28% (18/65) in the NoTX group (P = .50, by 2 test). Results from multivariate logistic regression showed that treatment had no significant impact on outcome (Odds ratio = 1.28, 95% confidence interval: 0.55-3.01; P = .57]. Patients with end-stage renal disease (6%), or stroke (13%) had significantly higher risk of progression (P < .05). None of the other clinical or demographic factors were significantly associated with the risk of progression. Conclusion: The results speak to the lack of efficacy of anticoagulation in the management of gastrocnemius and/or soleal vein thrombosis in the hospitalized patient. When measured by thrombus progression, treating these patients without anticoagulation appears to be equally efficacious as subjecting patients to anticoagulant therapy. A prospective, randomized clinical trial will be an important step in fully addressing this clinical dilemma.

UR - http://www.scopus.com/inward/record.url?scp=79952114274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952114274&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2010.05.102

DO - 10.1016/j.jvs.2010.05.102

M3 - Article

C2 - 20630686

AN - SCOPUS:79952114274

VL - 52

SP - 1251

EP - 1254

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 5

ER -